View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
July 20, 2011

AstraZeneca Celebrates Brilinta Approval

AstraZeneca has received US Food and Drug Administration (FDA) approval for blood-thinning medication Brilinta, considered vital to the company's future success. The FDA cleared the drug, used to reduce cardiovascular death and heart attacks in patients suffering from acute coronary

By cms admin

AstraZeneca has received US Food and Drug Administration (FDA) approval for blood-thinning medication Brilinta, considered vital to the company’s future success.

The FDA cleared the drug, used to reduce cardiovascular death and heart attacks in patients suffering from acute coronary syndromes, on the back of data compiled from 18,624 patients who participated in the PLATO study.

Brilinta’s approval comes with the condition that AstraZeneca launch a risk evaluation and mitigation strategy, including an educational outreach programme to warn doctors over the use of the drug in combination with high doses of aspirin.

AstraZeneca chief executive claimed that the approval represented a significant milestone for the company, particularly after the company suffered a setback as its dapagliflozin diabetes medication, co-developed with Bristol-Myers Squibb , was rejected by an FDA advisory committee.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology